Boston Scientific Acquires Nalu Medical for $600M: Peripheral Nerve Stimulation Meets the Neuromodulation Giant

Deal at a Glance

On October 17, 2025, Boston Scientific (NYSE: BSX) announced a definitive agreement to acquire Nalu Medical, a privately held, California-based medical technology company specializing in miniaturized neurostimulation systems for chronic pain. The transaction, valued at $600 million on a 100% basis, closed by approximately March 2026 and adds the first battery-free peripheral nerve stimulation (PNS) platform to Boston Scientific's established neuromodulation portfolio.

This acquisition is notable for several reasons: it fills a clear gap in Boston Scientific's pain portfolio, it brings Level-1 clinical evidence in an emerging therapy category, and it reflects a broader pattern of consolidation across the neuromodulation space -- with Medtronic announcing a $650 million deal for SPR Therapeutics just months later, and Globus Medical completing its $250 million acquisition of Nevro in April 2025.

Deal Background and Structure

A Relationship Eight Years in the Making

Boston Scientific was not entering unfamiliar territory with this acquisition. The company had been a strategic investor in Nalu Medical since 2017, holding an equity stake that predated the acquisition by nearly a decade. This long-standing relationship gave Boston Scientific unusual visibility into Nalu's technology, clinical pipeline, commercial trajectory, and management team -- reducing the information asymmetry that typically makes medtech acquisitions riskier than organic growth.

The transaction structure reflects this existing ownership. Boston Scientific paid approximately $533 million in upfront cash for the remaining equity it did not already own, bringing the total valuation to $600 million on a 100% basis before closing adjustments. The all-cash structure and the relatively clean deal terms -- customary closing conditions, no complex earn-outs disclosed -- are consistent with a tuck-in acquisition where the buyer already knows the asset intimately.

Timing and Strategic Context

The announcement came at a moment of significant momentum for both companies. Nalu was generating strong commercial traction, with projected 2025 sales exceeding $60 million and year-over-year growth projected above 25% for 2026. The company had recently achieved a major reimbursement milestone -- Aetna national coverage for PNS therapy in July 2025 -- and had published Level-1 clinical evidence from its COMFORT 2 randomized controlled trial in August 2025.

For Boston Scientific, the deal aligned with a broader capital allocation strategy that prioritizes acquisitions as a top priority for executing its category leadership approach. Citi Research analyst Joanne Wuensch characterized the transaction as consistent with Boston Scientific's approach of "bringing in private investments to expand the portfolio," while BTIG analysts noted the firm's "diverse product portfolio, targets of best-in-class sales growth, gradual operating margin improvement, and potential for upside from new products and recent M&A."

Financial Outlook

Boston Scientific provided clear guidance on the expected financial impact:

• 2026: Immaterial to adjusted earnings per share
• 2027: Slightly accretive to adjusted EPS
• Thereafter: Increasingly accretive
• GAAP basis: More dilutive due to amortization expense and acquisition-related charges

This cadence -- neutral in year one, slightly positive in year two, then increasingly accretive -- is typical for a commercial-stage tuck-in acquisition where the primary value creation comes from revenue growth and portfolio synergies rather than immediate cost cutting.

Nalu Technology Deep Dive: How Peripheral Nerve Stimulation Works

The Problem: Chronic Pain of Peripheral Nerve Origin

Chronic pain affects nearly 50 million adults in the United States alone. For many patients, the origin of their pain traces to peripheral nerves -- the network of nerves outside the brain and spinal cord that serve the shoulder, lower back, knee, and other extremity locations. When these nerves are damaged, compressed, or otherwise dysfunctional, they can generate persistent pain signals that are resistant to medication, physical therapy, and surgical intervention.

Traditional neurostimulation approaches, particularly spinal cord stimulation (SCS), target the spinal cord itself. While effective for many patients, SCS is not always the optimal approach for pain that originates in peripheral nerves. SCS requires placing electrodes in the epidural space around the spinal cord -- a more invasive procedure with a different risk profile than targeting individual peripheral nerves directly.

Peripheral nerve stimulation addresses this gap. Rather than stimulating the spinal cord, PNS delivers mild electrical impulses directly to the affected peripheral nerve, interrupting pain signals before they reach the brain. The concept has existed for decades, but practical implementation was limited by the size of implantable pulse generators and the need for surgical battery replacements.

Nalu's Architecture: Miniaturized and Battery-Free

Nalu Medical solved the fundamental engineering challenge of PNS through a clever architectural decision: eliminating the battery from the implant entirely.

The Nalu Neurostimulation System consists of three core components:

1. Micro-Implantable Pulse Generator (micro-IPG): A miniaturized implant, significantly smaller than traditional IPGs, that is placed subcutaneously near the target peripheral nerve. Because it contains no battery, the implant can be dramatically smaller than conventional neurostimulation devices.

2. Therapy Disc: A small externally worn device that is placed over the implanted micro-IPG on the skin surface. The Therapy Disc provides wireless power to the implant and enables bidirectional communication. Nalu advanced the Therapy Disc design further in August 2025, launching a new version that is 39% smaller than the prior generation.

3. Smartphone App: Patients control their therapy -- adjusting stimulation settings, managing programs, and monitoring usage -- through a smartphone application, eliminating the need for a separate proprietary patient programmer.

The surgical procedure involves creating a small pocket for the micro-IPG and tunneling leads from the target nerve to connect to the device. Once the wound heals, the Therapy Disc is placed externally over the implant to deliver power and stimulation parameters. A trial period (up to 30 days) allows the physician and patient to assess efficacy before committing to a permanent implant.

Why Battery-Free Matters

The absence of a battery inside the implant has several clinically meaningful implications:

• Smaller implant size: Without the volume occupied by a battery cell, the micro-IPG can be miniaturized to a form factor that is more comfortable for patients and less invasive to implant. There are no reports of "pocket pain" in the COMFORT clinical trials -- a common complication with traditional implanted neurostimulation devices where the IPG causes discomfort at the implant site.

• No battery replacement surgeries: Conventional implantable neurostimulators require surgical replacement when the battery depletes, typically every 3-9 years depending on usage and device type. Each replacement surgery carries risks of infection, lead damage, and scarring. Nalu's architecture eliminates this entirely.

• Simpler surgical technique: The smaller device size enables a less invasive implantation procedure, which may expand the pool of physicians who can perform the implant and reduce procedure time and cost.

Proprietary Waveform Technology

Beyond the battery-free architecture, Nalu employs a proprietary pulse stimulation pattern waveform designed to invoke multiple mechanisms of action from a single waveform. The system also supports scheduling functionality that can cycle through up to four multi-area programs automatically in sequence or random order, allowing treatment of multiple pain targets or prevention of therapy habituation.

Clinical Evidence: The COMFORT Trials

COMFORT Randomized Controlled Trial

The COMFORT study was a post-market, multicenter, randomized, controlled trial evaluating the Nalu PNS system across a variety of peripheral pain targets, including the shoulder, lower back, knee, and ankle/foot. The study was designed to generate 3-year data demonstrating sustained pain relief and quality-of-life improvements.

The primary endpoint was met, with Nalu PNS outperforming conventional care alone (p < 0.001). Key results at published time points:

At 24 months, the average pain reduction from baseline was 67%, with pain scores declining from 7.5 +/- 1.2 to 2.4 +/- 1.7 (p<0.001). All patient-reported outcomes -- including quality of life, mood, and functionality -- achieved statistical significance at every measured time point.

The safety profile was notably strong. No serious adverse device effects were reported throughout the study, and the vast majority of patients found the external components comfortable to wear. The absence of pocket pain, a common concern with traditional neurostimulation devices, was specifically highlighted.

COMFORT 2 Randomized Controlled Trial

Published on July 30, 2025, in the peer-reviewed journal Chronic Pain & Management, COMFORT 2 was designed as a confirmatory study. Its results provided the first Level-1 confirmatory evidence for a permanently implanted PNS device for treating chronic pain -- a significant milestone for the field.

COMFORT 2 results showed improved net health outcomes with statistically significant gains across all efficacy metrics:

• 79% of patients reached an average pain relief of 64% at six months
• Results were consistent with the COMFORT trial outcomes
• The study confirmed the positive clinical outcomes seen in the first COMFORT RCT

Dr. Mitch Engle, lead author of the COMFORT 2 publication, stated: "The outcomes from COMFORT 2 confirm what we have seen clinically -- that PNS therapy with the Nalu PNS System results in clinically significant improvement in patient symptoms, quality of life, and general well-being. The fact that the results of COMFORT 2 are consistent with those from COMFORT further reinforces the clinical value of this important therapy in helping patients return to a satisfying life."

Real-World Evidence

Clinical trial results were reinforced by real-world data from more than 2,000 individuals, showing that 94% of patients achieved clinically meaningful improvement across a broad range of chronic peripheral nerve pain conditions. Additionally, real-world data demonstrated meaningful economic outcomes:

• 31% reduction in patients using opioids following Nalu PNS implant
• 22% reduction in pharmacy costs
• 61% reduction in outpatient costs
• 16% reduction in outpatient doctor visits

These health economic findings are relevant to payers and health systems evaluating PNS therapy coverage.

Reimbursement Milestone

In July 2025, Nalu achieved a national payer milestone when Aetna established coverage for PNS therapy -- a significant development because national coverage decisions by major insurers are critical for scaling adoption of new device therapies. Additional regional coverage wins, including CareFirst BCBS recognizing the Nalu system as medically necessary for chronic peripheral pain (covering 3.5 million lives), further expanded patient access.

Boston Scientific's Neuromodulation Portfolio: Before and After

Before the Acquisition

Prior to the Nalu acquisition, Boston Scientific's neuromodulation portfolio covered three primary therapy categories:

Notably absent from this portfolio was a peripheral nerve stimulation device. PNS targets a distinct patient population -- those with chronic pain originating from specific peripheral nerves rather than from the spinal cord or vertebrogenic sources -- and represents a different point in the treatment continuum.

The Gap and the Fill

Jim Cassidy, President of Neuromodulation at Boston Scientific, articulated the strategic rationale clearly:

"Peripheral nerve stimulation is an exciting field with a significant unmet patient need. Adding the highly differentiated Nalu Medical technology complements our existing therapies -- including spinal cord stimulation, basivertebral nerve ablation and radiofrequency ablation -- enabling us to deliver advanced pain relief options to a wider variety of patient populations."

The key strategic insight is that PNS does not compete with SCS or other existing Boston Scientific therapies. Instead, it addresses a different segment of the chronic pain population -- patients whose pain is driven by specific peripheral nerve pathology rather than spinal or central mechanisms. By adding PNS, Boston Scientific can now offer interventional pain physicians a comprehensive suite of options:

• PNS for peripheral nerve pain (new, via Nalu)
• SCS for trunk and limb pain via dorsal column stimulation (WaveWriter Alpha)
• BVN ablation for vertebrogenic low back pain (Intracept)
• RF ablation for targeted nerve ablation (existing portfolio)
• DBS for movement disorders (Vercise Genus)

This breadth matters because pain physicians typically treat patients across multiple pain etiologies. A manufacturer that can supply solutions across the full spectrum of interventional pain therapies becomes a more valuable partner to the clinical community.

The Chronic Pain Market and the Shift Toward Targeted Therapies

Market Size and Growth

The neuromodulation market is substantial and growing. Various market research estimates place the global neuromodulation market at approximately $6.3-$7.4 billion in 2025, projected to reach $10.9-$19.5 billion by the mid-2030s, depending on scope and methodology. The spinal cord stimulation segment alone was valued at approximately $3.5 billion in 2025.

Pain management accounts for the largest share of neuromodulation revenue, estimated at roughly 45% of the total market. Within pain management, spinal cord stimulation has historically dominated, but peripheral nerve stimulation is emerging as a significant and growing subsegment.

The Opioid Crisis and Non-Pharmacologic Alternatives

The backdrop to growth in neurostimulation therapies is the ongoing opioid crisis in the United States. With nearly 50 million American adults affected by chronic pain and mounting concern about opioid dependence and overdose, there is strong clinical and policy interest in non-pharmacologic alternatives. The CDC, FDA, and major medical societies have issued guidelines prioritizing non-opioid approaches to chronic pain management.

Neurostimulation devices -- including SCS, PNS, and dorsal root ganglion (DRG) stimulation -- offer a drug-free, reversible approach to pain management. The demonstrated reduction in opioid use following Nalu PNS implantation (31% in real-world data) directly addresses this priority.

The Trend Toward Minimally Invasive and Targeted Approaches

The broader trajectory in interventional pain medicine is toward less invasive, more targeted therapies. This trend favors technologies like Nalu's micro-IPG over traditional large-pocket neurostimulators, and it favors peripheral nerve targeting over broader spinal cord approaches when the pain etiology is amenable.

Key factors driving this shift:

• Patient preference: Less invasive procedures with shorter recovery times
• Payer economics: Lower procedural costs and reduced downstream healthcare utilization
• Clinical evidence: Growing body of RCT data supporting targeted approaches
• Technology enablers: Miniaturization, wireless power, and smartphone controls making smaller implants practical

Competitive Landscape

The neuromodulation space is experiencing a wave of consolidation, with multiple major acquisitions reshaping the competitive picture in 2025-2026.

Major Acquisitions in Neuromodulation (2025-2026)

PNS Competitive Landscape

The peripheral nerve stimulation market includes several distinct approaches:

Nalu Medical (now Boston Scientific): Permanent implant with battery-free micro-IPG. Differentiated by miniaturization, wireless power, smartphone control, and Level-1 clinical evidence from two RCTs. Targets chronic peripheral nerve pain in shoulder, lower back, and knee.

SPR Therapeutics (acquired by Medtronic): Temporary, percutaneous PNS system. The SPRINT system threads a hair-thin MicroLead beneath the skin near a targeted nerve, connected to a wearable external pulse generator. Therapy duration is up to 60 days before the lead is withdrawn. No permanent implant required. Positions earlier in the care continuum as a bridge therapy.

Curonix: Independent competitor in the PNS space.

Abbott: Offers both SCS and has presence in the broader neuromodulation space, competing across pain management modalities.

Medtronic: Prior to the SPR announcement, Medtronic's neuromodulation portfolio included spinal cord stimulation (Inceptiv closed-loop SCS system) and deep brain stimulation. The SPR acquisition adds a temporary PNS option, complementing its permanent SCS offerings.

The SCS Competitive Landscape

Spinal cord stimulation remains the larger and more established segment:

The entry of Globus Medical -- traditionally an orthopedic and spine company -- into neuromodulation via the Nevro acquisition signals growing interest from adjacent medtech companies in the chronic pain space. Globus CEO Dan Scavilla described the deal as positioning the company to "expand into new markets for future growth" and characterized the neuromodulation opportunity at approximately $2.5 billion.

Regulatory Pathway for Neurostimulation Devices

The regulatory pathway for neurostimulation devices varies significantly depending on the type of stimulation, the anatomical target, and the associated risk profile. Understanding these distinctions is important for anyone evaluating the competitive landscape or considering development of neurostimulation technologies.

FDA Classification Framework

The FDA classifies neurological devices into three tiers based on risk:

Peripheral Nerve Stimulation: 510(k) Pathway (Class II)

PNS devices are regulated as Class II devices and typically enter the market through the 510(k) pathway. The 510(k) process requires the manufacturer to demonstrate that the device is substantially equivalent to a legally marketed predicate device -- meaning it has the same intended use and similar technological characteristics.

Nalu Medical received FDA 510(k) clearance for its neurostimulation system in 2019 (K183579 and K191435, FDA product code GZF). The 510(k) pathway for PNS is relatively efficient compared to PMA, with typical review timelines of 90 days and development costs that are an order of magnitude lower than Class III devices.

This regulatory pathway has strategic implications. The 510(k) route allows faster market entry for PNS innovators, but it also means lower barriers to entry for competitors -- which helps explain why the PNS space has attracted multiple entrants and significant acquisition interest.

Spinal Cord Stimulation: Mixed Pathway (Primarily PMA)

Despite also targeting chronic pain, spinal cord stimulation devices have historically been regulated more stringently. Many SCS devices received original approval through the PMA pathway (Class III), though subsequent devices and iterations have used both PMA supplements and, in some cases, 510(k) clearances. This mixed regulatory heritage reflects the longer clinical history of SCS and the FDA's approach to devices that were on the market before the Medical Device Amendments of 1976.

The practical effect is that SCS devices often face a more demanding regulatory burden than PNS devices, which influences development timelines and competitive dynamics.

Deep Brain Stimulation: PMA Pathway (Class III)

DBS devices, which involve implanting electrodes directly into brain tissue, are classified as Class III and require PMA. The PMA process is the most rigorous FDA pathway, requiring comprehensive clinical data, design validation, and manufacturing facility inspections. Boston Scientific's Vercise DBS system, for example, was approved through the PMA pathway in 2017.

Strategic Implications of Regulatory Classification

The classification differences across neurostimulation modalities create a stratified competitive landscape:

For Boston Scientific, acquiring a 510(k)-cleared PNS device that already has Level-1 clinical evidence and commercial traction represents significant value. The company gains market access in a new therapy segment without the cost and timeline risk of internal development -- and the 510(k) clearance provides a predicate for future product iterations.

Implications for the Neuromodulation Industry

The Consolidation Pattern

The cluster of acquisitions in 2025-2026 -- Boston Scientific/Nalu ($600M), Medtronic/SPR ($650M), and Globus Medical/Nevro ($250M) -- signals a decisive shift in the neuromodulation industry. Large strategics are moving aggressively to assemble comprehensive pain portfolios, and they are paying significant premiums for differentiated technology and clinical evidence.

Several patterns emerge from this deal activity:

Portfolio completeness is the objective. Each acquirer is filling a specific gap. Boston Scientific needed PNS. Medtronic needed a minimally invasive, non-permanent option for earlier intervention. Globus needed a neuromodulation entry point. The pattern suggests that companies without comprehensive pain portfolios may face competitive pressure to acquire or be left behind.

Clinical evidence drives valuation. Nalu's Level-1 evidence from two RCTs, combined with real-world data from over 2,000 patients, provided the clinical validation that justified a $600 million price tag for a company generating ~$60 million in revenue. That is roughly a 10x revenue multiple -- a premium that reflects the value of clinical differentiation in a market where payers increasingly demand evidence for coverage decisions.

Prior investment relationships reduce deal risk. All three major acquisitions in this cycle involved some degree of prior relationship or visibility. Boston Scientific had been an investor in Nalu since 2017. The pattern of strategic investors converting equity stakes into full acquisitions reduces integration risk and accelerates the path to commercial synergy.

The PNS Subsegment Is Emerging as a Strategic Priority

For years, peripheral nerve stimulation was a niche within the broader neurostimulation market, overshadowed by the much larger SCS segment. The 2025-2026 acquisition wave changes that dynamic. With Boston Scientific and Medtronic -- the two largest players in neuromodulation -- both acquiring PNS companies within months of each other, PNS has moved from niche to strategic imperative.

The logic is straightforward. PNS addresses a patient population that SCS does not optimally serve. The therapy is less invasive than SCS implantation. The battery-free micro-IPG approach eliminates the need for revision surgeries. And the clinical evidence base, particularly from Nalu's COMFORT program, has reached a maturity level that satisfies payers.

What This Means for Patients, Physicians, and the Industry

For patients with chronic peripheral nerve pain, the acquisition is likely to accelerate access. Boston Scientific's global commercial infrastructure -- its sales force, physician training programs, and payer relationships -- can scale Nalu's technology far faster than Nalu could have done independently. The Aetna national coverage decision established a reimbursement beachhead that Boston Scientific can now leverage across additional payers.

For interventional pain physicians, the deal means more therapeutic options from fewer vendors. A physician who currently uses Boston Scientific's WaveWriter SCS system will now have a PNS option from the same manufacturer, simplifying training, inventory management, and vendor relationships.

For the broader medtech industry, the message is clear: in neuromodulation, the window for independent PNS companies may be closing. Nalu, SPR, and Nevro have all been acquired. The remaining independent PNS players -- Curonix and others -- face a market where their largest potential acquirers have already made their moves. The question is whether additional consolidation will follow, or whether the next competitive dynamic will shift to the commercial battle between Boston Scientific's permanent, battery-free PNS and Medtronic's temporary, percutaneous PNS -- two fundamentally different approaches to the same clinical problem, now backed by the two largest companies in neuromodulation.

One thing is certain: the era of neuromodulation as a one-modality, one-size-fits-all approach to chronic pain is ending. The future belongs to targeted, evidence-based therapies that match the right technology to the right patient at the right point in their care journey. Boston Scientific's acquisition of Nalu Medical is a clear bet on that future -- and the $600 million price tag suggests the company is confident the market will validate that bet.